For more than 30 years, Pfizer has developed and implemented a variety of innovative partnerships designed to address new and ongoing health challenges. The Pfizer Naloxone Access Program reflects this commitment to improving health outcomes by expanding access to medicines and ensuring patient safety through educational activities associated with appropriate use of prescription medicines.
Since 2017, Pfizer has partnered with Direct Relief to make overdose-reversing naloxone available at no cost to qualified U.S. nonprofit health care providers and local public health departments on the front lines of the rising opioid epidemic. To date, more than 337,000 naloxone doses have been delivered to over 480 health care facilities and public health departments across 48 states and U.S. territories.
.jpg)
Share this page
